VBI Vaccines Inc. (NASDAQ:VBIV) Sees Significant Growth in Short Interest

VBI Vaccines Inc. (NASDAQ:VBIV) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 709,500 shares, a growth of 145.4% from the March 31st total of 289,100 shares. Currently, 2.7% of the company’s stock are sold short. Based on an average daily volume of 445,600 shares, the short-interest ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

Separately, StockNews.com assumed coverage on VBI Vaccines in a research note on Friday. They issued a “sell” rating for the company.

VBI Vaccines Price Performance

NASDAQ:VBIV opened at $0.57 on Friday. VBI Vaccines has a 1-year low of $0.45 and a 1-year high of $3.47. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.61.

About VBI Vaccines

VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.